Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H16F3NO4 |
| Molecular Weight | 439.3833 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C(=O)C1=CN(CC2=CC=CC=C2)C3=C1C=C(C=C3)C4=CC=C(OC(F)(F)F)C=C4
InChI
InChIKey=ODXQFEWQSHNQNI-UHFFFAOYSA-N
InChI=1S/C24H16F3NO4/c25-24(26,27)32-18-9-6-16(7-10-18)17-8-11-21-19(12-17)20(22(29)23(30)31)14-28(21)13-15-4-2-1-3-5-15/h1-12,14H,13H2,(H,30,31)
| Molecular Formula | C24H16F3NO4 |
| Molecular Weight | 439.3833 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://adisinsight.springer.com/drugs/800021321Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/15214776
https://www.ncbi.nlm.nih.gov/pubmed/18392333
https://www.ncbi.nlm.nih.gov/pubmed/17276980
Sources: http://adisinsight.springer.com/drugs/800021321
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/15214776
https://www.ncbi.nlm.nih.gov/pubmed/18392333
https://www.ncbi.nlm.nih.gov/pubmed/17276980
Tiplasinin (PAI-039) is an orally efficacious and selective plasminogen activator inhibitor-1 (PAI-1) inhibitor. Tiplasinin bound specifically to the active conformation of PAI-1 and exhibited reversible inactivation of PAI-1 in vitro. Tiplaxtinin exhibited in vivo oral efficacy in two different models of acute arterial thrombosis. The remarkable preclinical safety and metabolic stability profiles of tiplaxtinin led to advancing the compound to Phase-I clinical trial for Thrombosis, which was later discontinued.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17276980
Rodents: Phase 1 animals receiving low-dose (1 mg/kg oral gavage) Tiplasinin demonstrated a 52% decrease in thrombus weight (TW) versus controls with significant reductions in active plasma PAI-1, while the high-dose (10 mg/kg oral gavage) group demonstrated a 23% reduction in TW versus controls
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18177924
Tiplaxtinin inhibited rhPAI-1 activity measured in vitro by
the fibrinolysis assay in a dose-dependent manner with IC50 22 uM
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:17:03 GMT 2025
by
admin
on
Mon Mar 31 18:17:03 GMT 2025
|
| Record UNII |
L396QIB983
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29750
Created by
admin on Mon Mar 31 18:17:03 GMT 2025 , Edited by admin on Mon Mar 31 18:17:03 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C77020
Created by
admin on Mon Mar 31 18:17:03 GMT 2025 , Edited by admin on Mon Mar 31 18:17:03 GMT 2025
|
PRIMARY | |||
|
PP-16
Created by
admin on Mon Mar 31 18:17:03 GMT 2025 , Edited by admin on Mon Mar 31 18:17:03 GMT 2025
|
PRIMARY | |||
|
L396QIB983
Created by
admin on Mon Mar 31 18:17:03 GMT 2025 , Edited by admin on Mon Mar 31 18:17:03 GMT 2025
|
PRIMARY | |||
|
393105-53-8
Created by
admin on Mon Mar 31 18:17:03 GMT 2025 , Edited by admin on Mon Mar 31 18:17:03 GMT 2025
|
PRIMARY | |||
|
Tiplasinin
Created by
admin on Mon Mar 31 18:17:03 GMT 2025 , Edited by admin on Mon Mar 31 18:17:03 GMT 2025
|
PRIMARY | |||
|
8418
Created by
admin on Mon Mar 31 18:17:03 GMT 2025 , Edited by admin on Mon Mar 31 18:17:03 GMT 2025
|
PRIMARY | |||
|
DTXSID30192548
Created by
admin on Mon Mar 31 18:17:03 GMT 2025 , Edited by admin on Mon Mar 31 18:17:03 GMT 2025
|
PRIMARY | |||
|
300000034376
Created by
admin on Mon Mar 31 18:17:03 GMT 2025 , Edited by admin on Mon Mar 31 18:17:03 GMT 2025
|
PRIMARY | |||
|
CHEMBL325441
Created by
admin on Mon Mar 31 18:17:03 GMT 2025 , Edited by admin on Mon Mar 31 18:17:03 GMT 2025
|
PRIMARY | |||
|
6450819
Created by
admin on Mon Mar 31 18:17:03 GMT 2025 , Edited by admin on Mon Mar 31 18:17:03 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|